BioXcel Therapeutics is a commercial-stage biopharmaceutical company that leverages artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology. Through a drug re-innovation approach, BioXcel utilizes existing approved drugs combined with data analytics and proprietary algorithms to identify new therapeutic applications, enhancing treatment options for various conditions. The company's primary product, IGALMI (BXCL501), is a sublingual film formulation that has been approved by the FDA for the acute management of agitation in patients with schizophrenia and bipolar disorder. In addition, BioXcel is advancing multiple programs targeting agitation related to Alzheimer’s disease and developing therapies for cancer through its subsidiary OnkosXcel Therapeutics. The company values patient focus, integrity, collaboration, and agility, aiming to improve the quality of life for patients and ensure meaningful healthcare solutions. Job seekers interested in pioneering innovative treatments and contributing to a dynamic company may find appealing opportunities within BioXcel Therapeutics.